SCHEMBL12900100

SCHEMBL12900100

O=C(Nc1ccccc1C(=O)O)c1ccc(-c2ccc3c(c2)OCCO3)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.51
▸ TP53 P04637 4/20 0.49
▸ PRSS12 P56730 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ ESRRG P62508 3/20 0.48
▸ ESR1 P03372 2/20 0.48
▸ FTO Q9C0B1 1/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ FABP3 P05413 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900103 0.94 FABP3 (0.53) HDAC6NPSR1TP53PRSS12MAPT
SCHEMBL12900105 0.89 FABP3 (0.55) NPSR1TP53PRSS12SMN1; SMN2ESRRG
SCHEMBL18573537 0.85 NPC1 (0.63) HDAC6TP53MAPTALDH1A1MEN1
SCHEMBL12900109 0.83 ALDH1A1 (0.49) TP53MAPTALDH1A1MEN1KMT2A
SCHEMBL12900093 0.82 NPC1 (0.49) NPSR1TP53MAPTALDH1A1MEN1
SCHEMBL7239351 0.81 PRSS12 (0.54) NPSR1TP53PRSS12SMN1; SMN2KDM4E
SCHEMBL6246675 0.80 HDAC6 (0.72) HDAC6NPSR1TP53ALDH1A1MEN1
SCHEMBL18573642 0.78 NPC1 (0.63) HDAC6TP53MAPTALDH1A1MEN1
SCHEMBL12900089 0.76 FABP3 (0.50) NPSR1TP53MAPTALDH1A1MEN1
SCHEMBL12758441 0.75 KMT2A (0.60) NPSR1TP53PRSS12ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
WO-2007035478-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment LDLR, APOB, FFAR1 HDAC6 3118/4885NPSR1 57/4885TP53 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback